Joan Carles

Joan Carles

UNVERIFIED PROFILE

Are you Joan Carles?   Register this Author

Register author
Joan Carles

Joan Carles

Publications by authors named "Joan Carles"

Are you Joan Carles?   Register this Author

72Publications

2910Reads

29Profile Views

Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.

N Engl J Med 2019 12 30;381(26):2506-2518. Epub 2019 Sep 30.

From the Erasmus Medical Center, Rotterdam, the Netherlands (R.W.); the Institute of Cancer Research and the Royal Marsden Hospital, London (J.B.); Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); Institut Gustave Roussy and University of Paris Sud, Villejuif (K.F.), Jean Godinot Institute and Reims Champagne-Ardenne University, Reims (J.-C.E.), Foch Hospital, Suresnes (C.T.), Hôpital d'Instruction des Armées Bégin, Saint Mandé (C.H.), and Sanofi, Europe Medical Oncology, Paris (C.G.-R.) - all in France; Institut de Recherche Clinique, Université Catholique de Louvain, Louvain, Belgium (B.T.); the Department of Urology, Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona, Hamburg (C.W.), and Studienpraxis Urologie, Nürtingen (S.F.) - both in Germany; the Medical University of Vienna, Vienna (G.K.); Alexandra Hospital, National and Kapodistrian University of Athens, Athens (A.B.); Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona (J.C.); Azienda Ospedaliera Universitaria Integrata, Verona, and Fondazione Policlinico Agostino Gemelli IRCCS, Rome - both in Italy (R.I.); Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic (B.M.); Landspitali University Hospital, Reykjavik, Iceland (Á.S.); Sanofi, Global Medical Oncology, Cambridge, MA (A.O.); and 12 de Octubre University Hospital, Madrid (D.C.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1911206DOI Listing
December 2019

Towards a New Classification for Metastatic Prostate Cancer.

Eur Urol 2019 03 19;75(3):383-384. Epub 2018 Nov 19.

Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2018.10.058DOI Listing
March 2019

Targeting DNA Repair Defects for Precision Medicine in Prostate Cancer.

Curr Oncol Rep 2019 Mar 27;21(5):42. Epub 2019 Mar 27.

Prostate Cancer Translational Research Group, Vall d'Hebron Institute of Oncology (VHIO), Cellex Center, Natzaret 115-117, 08035, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0790-6DOI Listing
March 2019

Nanoparticles as theranostic vehicles in prostate cancer.

Ann Transl Med 2019 Mar;7(Suppl 1):S29

Vall d'Hebron Institute of Oncology, Vall d' Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/atm.2019.01.77DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462597PMC
March 2019

The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score.

Eur Urol 2018 07 20;74(1):17-23. Epub 2017 Sep 20.

Department of Urology, Ludwig-Maximilians University (LMU) Munich, Munich, Germany; Janssen Research & Development, Los Angeles, California, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2017.08.035DOI Listing
July 2018

Serum Testosterone Levels in Prostate Cancer Patients Undergoing Luteinizing Hormone-Releasing Hormone Agonist Therapy.

Clin Genitourin Cancer 2018 04 2;16(2):e491-e496. Epub 2017 Dec 2.

Department of Urology, Vall d'Hebron Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2017.10.025DOI Listing
April 2018

Detection of circulating tumor DNA for advanced bladder cancer: where are we going?

Transl Androl Urol 2018 Mar;7(Suppl 1):S101-S103

Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tau.2018.01.01DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5881193PMC
March 2018

Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m) and the Currently Approved Dose (25 mg/m) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA.

J Clin Oncol 2017 Oct 15;35(28):3198-3206. Epub 2017 Aug 15.

Mario Eisenberger, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Anne-Claire Hardy-Bessard, Centre Armoricain d'Oncologie, Centre Armoricain de Radiothérapie, d'Imagerie Médicale et d'Oncologie-Hôpital Privé Des Côtes d'Armor, Plérin; Loïc Mourey, Institut Claudius Regaud, l'Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse; Mustapha Chadjaa, Sanofi, Vitry-sur-Seine, France; Choung Soo Kim, Asan Medical Center, Seoul, South Korea; Lajos Géczi, National Institute of Oncology, Budapest, Hungary; Daniel Ford, City Hospital, Cancer Centre at Queen Elizabeth Hospital, Birmingham; Johann de Bono, Prostate Cancer Targeted Therapy Team, Royal Marsden National Health Service Foundation Trust/The Institute of Cancer Research, Sutton, United Kingdom; Joan Carles, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona; Phillip Parente, Eastern Health Clinical School, Monash University, Box Hill Hospital, Melbourne, Victoria, Australia; Albert Font, Institut Català d'Oncologia, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; Gabriel Kacso, Iuliu Hatieganu Medical University, Amethyst Radiology Therapeutic Center, Cluj, Romania; Wenping Zhang, Sanofi, Bridgewater, NJ; and John Bernard, Sanofi, Cambridge, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.72.1076DOI Listing
October 2017

Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors.

Target Oncol 2017 06;12(3):277-288

Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, P. Vall d'Hebron 119, 08035, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11523-017-0490-9DOI Listing
June 2017

Unveiling changes in the landscape of patient populations in cancer early drug development.

Oncotarget 2017 Feb;8(8):14158-14172

Department of Medical Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.13258DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355170PMC
February 2017

Free Testosterone During Androgen Deprivation Therapy Predicts Castration-Resistant Progression Better Than Total Testosterone.

Prostate 2017 01 1;77(1):114-120. Epub 2016 Nov 1.

Department of Urology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/pros.23256
Publisher Site
http://dx.doi.org/10.1002/pros.23256DOI Listing
January 2017

Targeting fibroblast growth factor receptors and immune checkpoint inhibitors for the treatment of advanced bladder cancer: New direction and New Hope.

Cancer Treat Rev 2016 Nov 1;50:208-216. Epub 2016 Oct 1.

Vall d'Hebron Institute of Oncology, Vall d' Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2016.09.018DOI Listing
November 2016

Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis.

Lancet Oncol 2016 Oct 27;17(10):1386-1395. Epub 2016 Aug 27.

Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain; School of Medicine, University of Barcelona, Barcelona, Catalonia, Spain; Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(16)30297-2DOI Listing
October 2016

Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.

Lancet Oncol 2016 Sep 26;17(9):1306-16. Epub 2016 Jul 26.

The Centre for Cancer Research and Cell Biology, Queen's University Belfast, Northern Ireland; Northern Ireland Cancer Centre, Belfast, Northern Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(16)30173-5DOI Listing
September 2016

Role of immunotherapy in castration-resistant prostate cancer (CRPC).

BJU Int 2014 Mar 12;113(3):367-75. Epub 2013 Apr 12.

Genitourinary, Sarcoma, and Central Nervous System Tumor Program, Medical Oncology Department, Universitat Autònoma Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bju.12110DOI Listing
March 2014

Metabolic syndrome increases the risk of aggressive prostate cancer detection.

BJU Int 2013 Jun 9;111(7):1031-6. Epub 2012 Aug 9.

Department of Urology, Universitat Autónoma de Barcelona, Paseo Vall d'Hebron 119-129, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1464-410X.2012.11406.xDOI Listing
June 2013

BRAF V600E and KRAS G12S mutations in peripheral nerve sheath tumours.

Histopathology 2013 Feb 27;62(3):499-504. Epub 2012 Nov 27.

Department of Oncology, Hospital Universitari Vall d'Hebron, Universitat Autonoma de Barcelona, Passeig de la Vall d’Hebron 119–129, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/his.12021DOI Listing
February 2013

Evaluation of patients with metastatic renal cell carcinoma after failure of first-line treatment.

Cancer Metastasis Rev 2012 Sep;31 Suppl 1:S3-9

Medical Oncology Service, Hospital Universitari Vall d'Hebron, Passeig de la Vall d'Hebron, 119-129, 08035, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10555-012-9353-0DOI Listing
September 2012

Recommendations for the optimal management of early and advanced urothelial carcinoma.

Cancer Treat Rev 2012 Aug 23;38(5):431-41. Epub 2011 Nov 23.

Medical Oncology Department, Hospital Universitario 12 de Octubre, Avda. De Córdoba, S/N. 28041 Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2011.10.004DOI Listing
August 2012

Cisplatin and gemcitabine administered every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function.

Eur J Cancer 2012 Aug 16;48(12):1816-21. Epub 2012 May 16.

Department of Medical Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S095980491200322
Publisher Site
http://dx.doi.org/10.1016/j.ejca.2012.04.002DOI Listing
August 2012

Emerging therapies for urothelial cancer.

Cancer Treat Rev 2012 Jun 22;38(4):311-7. Epub 2011 Nov 22.

Genitourinary, Sarcoma and Central Nervous System Tumors Program, Medical Oncology Department, Vall d'Hebron University Hospital, Universitat Autonoma Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2011.10.007DOI Listing
June 2012

Castration-resistant metastatic prostate cancer: current status and treatment possibilities.

Clin Transl Oncol 2012 Mar;14(3):169-76

Servicio de Oncología, Instituto de Oncología de la Vall d'Hebron, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12094-012-0780-8DOI Listing
March 2012

SEOM clinical guidelines for the treatment of invasive bladder cancer.

Clin Transl Oncol 2011 Aug;13(8):552-9

Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12094-011-0696-8DOI Listing
August 2011

Molecular basis for the treatment of renal cell carcinoma.

Clin Transl Oncol 2010 Jan;12(1):15-21

Department of Medical Oncology, Vall d'Hebrón University Hospital, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s12094-010-0461
Web Search
http://link.springer.com/10.1007/s12094-010-0461-4
Publisher Site
http://dx.doi.org/10.1007/s12094-010-0461-4DOI Listing
January 2010

Impact of PSA implementation and combined radiation and hormonal therapy (RT+HT) on outcome of prostate cancer patients.

Eur J Cancer 2009 Nov 20;45(16):2804-9. Epub 2009 Jul 20.

Department of Medical Oncology, Hospital Universitari del Mar-IMIM Passeig Marítim 25-29, Barcelona E-08003, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2009.06.019DOI Listing
November 2009

Management and interpretation of novel toxicities of molecular targeted therapies: renal toxicities.

Eur J Cancer 2009 Sep;45 Suppl 1:309-17

Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0959-8049(09)70045-0DOI Listing
September 2009

Expression of cyclooxygenase-2 mRNA in peripheral blood of head and neck cancer patients and in healthy controls. A pilot study.

Acta Otolaryngol 2007 Jan;127(1):71-5

Oncology Department of Hospital Clinic, Faculty of Medicine, University of Medicine, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/00016480600672576DOI Listing
January 2007